NeuroMuscular Emergencies

Medical

$9.99 · Designed for iPad. Not verified for macOS.

GBS, myasthenic crisis, botulism, periodic paralysis — recognition, respiratory thresholds, IVIg protocols and ICU management. 20/30/40 rule · NICE · EAN. IMPORTANT: This app is intended for use by qualified healthcare professionals only. Always seek the advice of a qualified clinician before making any medical or prescribing decisions. Neuromuscular Emergencies is a comprehensive evidence-based reference for the recognition and management of acute neuromuscular conditions. Built for neurologists, intensivists, emergency physicians, and allied health professionals managing patients with neuromuscular respiratory failure. GUILLAIN-BARRE SYNDROME - Brighton diagnostic criteria and clinical features - GBS disability scale and IGOS prognosis score - IVIg protocol: 0.4g/kg/day for 5 days with full administration guide - Plasma exchange protocol: 200-250 mL/kg over 5 sessions - Six GBS variants: AIDP, MFS, AMAN, AMSAN, PCB, pure sensory - Anti-GQ1b, anti-GM1, anti-GD1a antibody significance - Supportive care: autonomic monitoring, pain management, VTE prophylaxis - Anti-ganglioside antibody guide and variant recognition MYASTHENIC CRISIS - Recognition of impending respiratory failure: single breath count, paradoxical breathing - Myasthenic vs cholinergic crisis - SLUDGE, pupil changes, clinical comparison table - 20/30/15 rule: VC below 20, NIF below -30, MEP below 40 - IVIg and plasma exchange protocols - MGTX trial evidence - Pyridostigmine hold during ICU admission - New agents: eculizumab (NICE approved), efgartigimod - Intubation considerations RESPIRATORY FAILURE IN NM DISEASE - 20/30/40 rule - visual dashboard of critical thresholds - Why SpO2 is unreliable in neuromuscular respiratory failure - Bedside vital capacity technique - 6-step protocol - Serial NIF measurement technique - Intubation criteria and weaning criteria - Peak cough flow assessment LAMBERT-EATON MYASTHENIC SYNDROME - LEMS vs MG clinical comparison table - Anti-VGCC antibody - pathophysiology and diagnosis - EMG pattern: incremental response at high-frequency stimulation - 3,4-Diaminopyridine (amifampridine) dosing and mechanism - Malignancy screen protocol - SCLC association BOTULISM - Five types: foodborne, wound, infantile, iatrogenic, inhalation - Four Ds: diplopia, dysarthria, dysphagia, descending paralysis - Fixed dilated pupils - key distinguishing feature - 7-step emergency protocol including PHE contact number - Heptavalent antitoxin - administration and timing - Wound debridement for injection drug use botulism CRITICAL ILLNESS WEAKNESS - CIM vs CIP comparison table - pathology, NCS, prognosis - Risk factors and prevention - MRC sum score - ICU-acquired weakness PERIODIC PARALYSIS - Five syndromes comparison: hypokalaemic PP types 1 and 2, hyperkalaemic PP, Andersen-Tawil, thyrotoxic PP - Andersen-Tawil triad: paralysis, cardiac arrhythmia, dysmorphic features - Thyrotoxic PP - propranolol protocol and electrolyte management NMJ DISORDERS OVERVIEW - Neuromuscular junction anatomy and physiology - Complete antibody target table - EMG patterns - SFEMG interpretation DRUG-INDUCED NEUROMUSCULAR DISEASE - Drugs to avoid in MG - Statin myopathy spectrum - Anti-HMGCR autoimmune myopathy - ICI neuromuscular toxicity: myasthenia, myositis, myocarditis overlap - Rhabdomyolysis management protocol ICU MONITORING - Monitoring frequency table by disease and severity - Bedside VC, NIF, single breath count, peak cough flow techniques - Bulbar function assessment protocol - Autonomic monitoring in GBS: bradycardia, BP lability management SOURCES AND REFERENCES 25 plus tappable references including EAN GBS Guidelines 2023, EAN/EFNS MG Guidelines, Dutch GBS Study Group IVIg trial, SID-GBS 2023, MGTX trial, REGAIN eculizumab trial, ADAPT efgartigimod trial, Brighton criteria, EMBRACE trial, PHE botulism guidelines and ABCD trial. DISCLAIMER This app is intended for use by qualified healthcare professionals only as a clinical decision-support and educational reference tool. It does not replace individual clinical assessment, local neurology protocols or official prescribing information.

Ratings & Reviews

  • This app hasn’t received enough ratings or reviews to display an overview.

The developer, ATIF ELNIL, indicated that the app’s privacy practices may include handling of data as described below. For more information, see the developer’s privacy policy .

  • Data Not Collected

    The developer does not collect any data from this app.

    Privacy practices may vary, for example, based on the features you use or your age. Learn More

    Accessibility

    The developer has not yet indicated which accessibility features this app supports. Learn More

    Information

    Seller
    • ATIF ELNIL
    Size
    • 4.5 MB
    Category
    • Medical
    Compatibility
    Requires iOS 26.4 or later.
    • iPhone
      Requires iOS 26.4 or later.
    • iPad
      Requires iPadOS 26.4 or later.
    • Mac
      Requires macOS 26.4 or later and a Mac with Apple M1 chip or later.
    • Apple Vision
      Requires visionOS 26.4 or later.
    Languages
    • English
    Age Rating
    16+
    Copyright
    • © 2026 Dr Atif Elnil. All rights reserved.
  • Privacy Policy

    • Supports

    • Family Sharing

      Up to six family members can use this app with Family Sharing enabled.

    More by ATIF ELNIL